This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
March 12, 2013 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a developer of transrenal molecular diagnostics, today announced that Chief Financial Officer
Stephen Zaniboni is scheduled to present a corporate overview at the 25
th Annual Roth OC Growth Stock Conference at the Ritz-Carlton Laguna Nigel, in
Dana Point, CA on
Tuesday, March 19, 2013 at
12:00 p.m. Mr. Zaniboni will be available for one-on-one meetings during the conference.
The presentation will be webcast live at
http://wsw.com/webcast/roth27/trov/ and can also be accessed through the investor relations page at
www.trovagene.com. A replay of the presentation will be available at
www.trovagene.com and will be archived for 30 days.
About Trovagene, Inc.
San Diego, California, Trovagene is developing its patented technology for the detection of transrenal DNA and RNA, short nucleic acid fragments, originating from normal and diseased cell death that cross the kidney barrier and can be detected in urine. Trovagene is leveraging its intellectual property in oncogene mutations via out-licensing and use of its transrenal technologies to extend oncogene mutation detection using urine as a sample. As a non-invasive and abundant sample, urine may overcome many of the cost and collection challenges associated with biopsy, as well as the volume limitations of blood.
Trovagene has a strong patent position as it relates to transrenal molecular testing. It has U.S. and European patent applications and issued patents that cover testing for HPV and other infectious diseases, cancer, transplantation, prenatal and genetic testing. In addition, it owns worldwide rights to nucleophosmin-1 (NPM1), an informative biomarker for acute myelogenous leukemia (AML) and mutations in the SF3B1 gene, which have been shown to be associated with chemotherapy response in chronic lymphocytic leukemia (CLL) patients, as well as other hematologic malignancies.